Nura Bio Completes $73.8M Series B
2026-06-22
Tweet
SOUTH SAN FRANCISCO, CA, Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, announced the completion of a $73.8M Series B financing.
Nura Bio, a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, announced the completion of a $73.8M Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs.
The financing, led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures, will fund the development of Nura Bio's clinical pipeline, including the Phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients.
The financing, led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures, will fund the development of Nura Bio's clinical pipeline, including the Phase 1b/2a study of NB-4746, its oral, brain-penetrant SARM1 inhibitor, which recently commenced dosing in ALS patients.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
